<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Commonly used ototoxicity grading scales</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Commonly used ototoxicity grading scales</h1>
<div class="graphic"><div class="figure"><div class="ttl">Commonly used ototoxicity grading scales</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">Grading scale</td> <td class="subtitle1">Description</td> <td class="subtitle1">Target population</td> <td class="subtitle1">Features</td> <td class="subtitle1">Limitations</td> </tr> <tr class="divider_bottom"> <td>Brock<br/> (Brock <span style="white-space: nowrap;">1991)<sup>[1]</sup></span></td> <td>Designed to grade hearing loss progression from high to low frequencies in the configuration commonly associated with ototoxic cancer therapy; hearing loss is graded on 5-point scale</td> <td>Pediatric</td> <td>Widely used; baseline assessment not required</td> <td>Does not capture hearing loss &lt;40 dB, misses significant functional deficits</td> </tr> <tr class="divider_bottom"> <td>ASHA<br/> <span style="white-space: nowrap;">(1994)<sup>[2]</sup></span></td> <td>Hearing is compared with baseline in absolute terms (ie, presence/absence of hearing loss in comparison with baseline)</td> <td>Pediatric and adult</td> <td>Designed for early detection of hearing loss</td> <td>Does not classify severity of hearing loss; baseline assessment is required</td> </tr> <tr class="divider_bottom"> <td>Muenster<br/> (Schmidt <span style="white-space: nowrap;">2007)<sup>[3]</sup></span></td> <td>8-point scale accounts for minimal hearing loss (&gt;10 to 20 dB), subgroups within major classifications, and tinnitus</td> <td>Pediatric</td> <td>Designed for early detection of hearing loss</td> <td>Complexity of use</td> </tr> <tr class="divider_bottom"> <td>Chang<br/> (Chang &amp; Chinosornvatana <span style="white-space: nowrap;">2010)<sup>[4]</sup></span></td> <td>Modification of Brock scale with similar configuration and expansion to 7-point scale; grades hearing loss &gt;20 dB and measures interval frequencies (ie, 3000 and 6000 Hz)</td> <td>Pediatric</td> <td>Addresses functional deficits; baseline assessment not required</td> <td>Complexity of use</td> </tr> <tr class="divider_bottom"> <td>NCI CTCAE, version 5<br/> <span style="white-space: nowrap;">(2017)<sup>[5]</sup></span></td> <td>4-point scale includes both objective and subjective criteria; grades are assigned based on threshold shift from baseline and actual hearing loss</td> <td>Pediatric and adult</td> <td>Familiar to oncologists; widely used in NCI-sponsored clinical trials</td> <td>Baseline assessment required</td> </tr> <tr class="divider_bottom"> <td>SIOP Boston<br/> (Brock <span style="white-space: nowrap;">2012)<sup>[6]</sup></span></td> <td>5-point scale designed to grade hearing loss progression from high to low frequencies; grades hearing loss &gt;20 dB; uses absolute hearing levels</td> <td>Pediatric</td> <td>Proposed through consensus of international working group; potential application across clinical trials worldwide; baseline assessment not required</td> <td>Limited reliability and validity testing to date</td> </tr> <tr> <td>TUNE grading system<br/> (Theunissen <span style="white-space: nowrap;">2014)<sup>[7]</sup></span></td> <td>7-point scale designed to provide insight into the effect of hearing loss on specific daily life situations (such as speech intelligibility and ability to appreciate ultrahigh sounds)</td> <td>Adults</td> <td>Includes subjective symptoms and threshold shifts at higher frequencies (up to 12.5 kHz); uses air conduction thresholds only; designed to represent the auditory system's real-world functionality</td> <td>Time-consuming to use; feasibility testing completed; needs external validation</td> </tr> </tbody></table></div><div class="graphic_footnotes">dB: decibels; ASHA: American Speech-Language-Hearing Association; Hz: Hertz; NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; SIOP: International Society of Pediatric Oncology Boston ototoxicity scale; kHz: kilo Hertz.</div><div class="graphic_reference">References:

<ol>
<li>Brock PR, Bellman SC, Yeomans EC, et al. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 1991; 19:295.</li>
<li>American Speech-Language-Hearing Association. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA 1994; 36(suppl 12):11.</li>
<li>Schmidt CM, Bartholomaus E, Deuster D, et al. [The "Muenster classification" of high frequency hearing loss following cisplatin chemotherapy]. HNO 2007; 55:299.</li>
<li>Chang KW, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol 2010; 28:1788.</li>
<li>Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href="https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf" target="_blank">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</li>
<li>Brock PR, Knight KR, Freyer DR, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol 2012; 30:2408.</li>
<li>Theunissen EA, Dreschler WA, Latenstein MN, et al. A new grading system for ototoxicity in adults. Ann Otol Rhinol Laryngol 2014; 123:711.</li>
</ol>

Adapted from: Landier W. Ototoxicity and cancer therapy. Cancer 2016; 122:1647. DOI: <a href="http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.29779/abstract" target="_blank">10.1002/cncr.29779</a>. Copyright © 2016 Wiley Periodicals, Inc. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href="/cdn-cgi/l/email-protection#334356415e5a40405a5c5d4073445a5f564a1d505c5e" target="_true"><span class="__cf_email__" data-cfemail="ec9c899e81859f9f8583829fac9b85808995c28f8381">[email protected]</span></a> or use the RightsLink service by clicking on the Request Permission link accompanying this article on Wiley Online Library (<a href="http://onlinelibrary.wiley.com" target="_blank">http://onlinelibrary.wiley.com</a>).</div><div id="graphicVersion">Graphic 109907 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
